<?xml version="1.0" encoding="UTF-8"?>
<?covid-19-tdm?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2021.753290</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>HLA-DR Expression Level in CD8<sup>+</sup> T Cells Correlates With the Severity of Children With Acute Infectious Mononucleosis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Luo</surname>
<given-names>Ying</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tang</surname>
<given-names>Guoxing</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ouyang</surname>
<given-names>Renren</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Minxia</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jiang</surname>
<given-names>Yuhuan</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Ting</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Xiwen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yin</surname>
<given-names>Botao</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Jin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wei</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Min</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Feng</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1135458"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wu</surname>
<given-names>Shiji</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Hou</surname>
<given-names>Hongyan</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1430412"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Laboratory Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology</institution>, <addr-line>Wuhan</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Clinical Laboratory, First Affiliated Hospital of Nanchang University</institution>, <addr-line>Nanchang</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Vladimir Jurisic, University of Kragujevac, Serbia</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Luca Hensen, Peter Doherty Institute for Infection and Immunity, Australia; Louise Rowntree, The University of Melbourne, Australia</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Feng Wang, <email xlink:href="mailto:fengwang@tjh.tjmu.edu.cn">fengwang@tjh.tjmu.edu.cn</email>; Shiji Wu, <email xlink:href="mailto:wilson547@163.com">wilson547@163.com</email>; Hongyan Hou, <email xlink:href="mailto:houhongyan89@163.com">houhongyan89@163.com</email>
</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Viral Immunology, a section of the journal Frontiers in Immunology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>03</day>
<month>11</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="collection">
<year>2021</year>
</pub-date>
<volume>12</volume>
<elocation-id>753290</elocation-id>
<history>
<date date-type="received">
<day>04</day>
<month>08</month>
<year>2021</year>
</date>
<date date-type="accepted">
<day>14</day>
<month>10</month>
<year>2021</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2021 Wang, Luo, Tang, Ouyang, Zhang, Jiang, Wang, Zhang, Yin, Huang, Wei, Huang, Wang, Wu and Hou</copyright-statement>
<copyright-year>2021</copyright-year>
<copyright-holder>Wang, Luo, Tang, Ouyang, Zhang, Jiang, Wang, Zhang, Yin, Huang, Wei, Huang, Wang, Wu and Hou</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>This study aimed to assess the host immune signatures associated with EBV infection and its clinical value in indicating the severity of children with acute infectious mononucleosis (IM).</p>
</sec>
<sec>
<title>Methods</title>
<p>Twenty-eight pediatric patients with IM aged 3&#x2013;8 years were enrolled. The immune phenotypes and cytokine secretion capability of T cells were detected.</p>
</sec>
<sec>
<title>Results</title>
<p>The percentages and absolute numbers of CD3<sup>+</sup> and CD8<sup>+</sup> T cells were significantly increased in IM patients compared with HCs. The percentages of Na&#xef;ve CD4<sup>+</sup> and CD8<sup>+</sup> T cells were decreased but with increased percentages of memory CD4<sup>+</sup> and CD8<sup>+</sup> T subsets. Our results showed the upregulation of active marker HLA-DR, TCR-&#x3b1;&#x3b2;, and inhibitory receptors PD-1, TIGIT in CD8<sup>+</sup> T cells from IM patients, which suggested that effective cytotoxic T cells were highly against EBV infection. However, EBV exposure impaired the cytokine (IFN-&#x3b3;, IL-2, and TNF-&#x3b1;) secretion capability of CD4<sup>+</sup> and CD8<sup>+</sup> T cells after stimulation with PMA/ionomycin <italic>in vitro</italic>. Multivariate analysis revealed that the percentage of HLA-DR<sup>+</sup> CD8<sup>+</sup> T cells was an independent prognostic marker for IM. The percentage of HLA-DR<sup>+</sup> CD8<sup>+</sup> T cells was significantly correlated with high viral load and abnormal liver function results.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>Robust expansion and upregulation of HLA-DR in CD8<sup>+</sup> T cells, accompanied with impaired cytokine secretion, were typical characteristics of children with acute IM. The percentage of HLA-DR<sup>+</sup> CD8<sup>+</sup> T cells might be used as a prominent marker not only for the early diagnosis but also for indicating the severity of IM.</p>
</sec>
</abstract>
<kwd-group>
<kwd>EBV</kwd>
<kwd>infectious mononucleosis</kwd>
<kwd>CD8<sup>+</sup> T cells</kwd>
<kwd>CD4<sup>+</sup> T cells</kwd>
<kwd>HLA-DR<sup>+</sup> CD8<sup>+</sup> T cells</kwd>
</kwd-group>
<contract-sponsor id="cn001">National Mega Project on Major Infectious Disease Prevention<named-content content-type="fundref-id">10.13039/501100018536</named-content>
</contract-sponsor>
<counts>
<fig-count count="6"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="38"/>
<page-count count="11"/>
<word-count count="4805"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Infectious mononucleosis (IM) is an acute infectious disease in children caused mainly by Epstein-Barr virus (EBV) infection (<xref ref-type="bibr" rid="B1">1</xref>). Epidemiological studies showed that the positive rate of EBV is estimated to be more than 90% worldwide (<xref ref-type="bibr" rid="B2">2</xref>). The typical clinical manifestations of children with IM include fever, sore throat, lymph node enlargement, hepatosplenomegaly, skin rash, eyelid edema (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>). However, the initial symptoms of IM are variable and lack specificity. Although IM presents as a self-revolving illness, some patients may develop serious complications, such as spleen rupture, malignancies, and EBV-related hemophagocytic syndrome (HPS) (<xref ref-type="bibr" rid="B5">5</xref>&#x2013;<xref ref-type="bibr" rid="B7">7</xref>). Therefore, accurate early diagnosis, timely treatment, and effective monitoring are important for children with acute IM.</p>
<p>The host immune system exerts a key function in the recognition and elimination of EBV infection, and the dysregulation of immune response contributes to the development and progression of disease (<xref ref-type="bibr" rid="B8">8</xref>). EBV preferentially infects B lymphocytes and results in the establishment of lifelong latent infection of the host (<xref ref-type="bibr" rid="B9">9</xref>). It is generally believed that these cells are rigorously controlled <italic>in vivo</italic> by cytotoxic T cells (CTLs) (<xref ref-type="bibr" rid="B10">10</xref>). Inconsistent with this, a robust T&#xa0;cell response is specific for lytic and latent cycle viral antigens (<xref ref-type="bibr" rid="B11">11</xref>,&#xa0;<xref ref-type="bibr" rid="B12">12</xref>). The intensive proliferation of CD8<sup>+</sup> T with typical form plays a critical role in the clearance of EBV infection, which also explains the reduced ratio of CD4/CD8 lymphocytes (<xref ref-type="bibr" rid="B13">13</xref>). Moreover, the depletion of CD8<sup>+</sup> T cells results in increased viral load and IM-like EBV infection in mice (<xref ref-type="bibr" rid="B14">14</xref>). Further studies demonstrated the importance of T cells and NK cells in controlling EBV infection in certain patients with immuno-deficiencies (<xref ref-type="bibr" rid="B15">15</xref>, <xref ref-type="bibr" rid="B16">16</xref>). Therefore, a deep investigation of EBV-associated host immune response in children with acute IM is necessary for understanding the pathogenesis of EBV and EBV-related diseases.</p>
<p>In this study, we compared the differences of lymphocyte subsets between IM patients and healthy controls (HCs). The subpopulations of Na&#xef;ve, memory/effector cells, the expression levels of active marker HLA-DR, co-stimulatory molecule CD28, T cell receptors (TCR-&#x3b1;&#x3b2;, TCR-&#x3b3;&#x3b4;), inhibitory receptors, and the cytokine secretion capabilities of CD4<sup>+</sup> T and CD8<sup>+</sup> T cells were evaluated in pediatric patients at the diagnosis of IM. Then CD8<sup>+</sup> T cells were subdivided into CD8<sup>high</sup> and CD8<sup>dim</sup> T cell populations depending on the intensity of fluorescence, and the differences of phenotypes between the two cell populations were compared. In addition, the subtypes of B cells and monocytes were also detected. Our study provided a comprehensive evaluation of mononuclear cells in peripheral blood, which is critically important for further elucidating the pathogenesis mechanisms during EBV infection.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s2_1">
<title>Patients</title>
<p>A total of 28 pediatric patients (19 males and 9 females) diagnosed with IM were included in this study from January to June 2021. None of these patients had previous evidence for an underlying immunodeficiency, and none of them received previous immunosuppressive drugs. In addition, 18 HCs (9 males and 9 females) were also recruited and determined by interview and physical examination. The exclusion criteria include HIV and HCV positive. This study was approved by the ethical committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. All of the subjects&#x2019; legal guardian/next of kin provided written informed consent for their participation in this study.</p>
</sec>
<sec id="s2_2">
<title>TBNK Lymphocyte Counting</title>
<p>The percentages and absolute numbers of CD4<sup>+</sup> T cells, CD8<sup>+</sup> T cells, B cells, and NK cells were determined using TruCOUNT tubes and BD Multitest 6-color TBNK ReagentKit (BD Biosciences) according to the manufacturer&#x2019;s instructions. In brief, 50 &#x3bc;l of whole blood was labeled with six-color TBNK Ab cocktail regent for 15 min at room temperature. After adding 450 &#x3bc;l of FACSlysing solution, samples were analyzed with FACSCanto flow cytometer using FACSCanto clinical software (BD Biosciences).</p>
</sec>
<sec id="s2_3">
<title>Lymphocyte Phenotypes, B Cell and Monocyte Subsets Analysis</title>
<p>Heparinized venous blood was collected from IM patients and HCs. The following monoclonal antibodies and reagents were added to 100 &#xb5;l whole blood for the analysis of lymphocyte phenotypes. The antibodies in tube 1 were anti-CD45-PerCP (BD phamingin, 2D1), anti-CD3-APC-H7 (BD phamingin, SK7), anti-CD4-V450 (BD phamingin, RPA-T4), anti-CD8-PE/Cy7 (BD phamingin, SK1), anti-CD28-PE (BD phamingin, L293), and anti-HLA-DR-APC (BD phamingin, L243). The antibodies in tube 2 were anti-CD45-PerCP (BD phamingin, 2D1), anti-CD3-APC-H7 (BD phamingin, SK7), anti-CD4-BV510 (BD phamingin, SK3), anti-CD45RA-FITC (BD phamingin, L48), anti-CD8-PE/Cy7 (BD phamingin, SK1), anti-CCR7-PE (BD phamingin, 3D12), anti-CD25-APC (BD phamingin, 2A3), and anti-CD127-BV421 (BD phamingin, HIL-7R-M21). The expression of TCR on T cells was detected using anti-CD45-PerCP (BD phamingin, 2D1), anti-TCR-&#x3b1;&#x3b2;-FITC (BD phamingin, WT31), anti-TCR-&#x3b3;&#x3b4;-PE (BD phamingin, 11F2), anti-CD3-APC/H7 (BD phamingin, SK7), anti-CD4-V450 (BD phamingin, RPA-T4), and anti-CD8-APC (BD phamingin, SK1). The subsets of B cells were detected using anti-CD38-FITC (BD phamingin, HB7), anti-CD19-PE/Cy7 (BD phamingin, SJ25C1), anti-CD27-PerCP (BD phamingin, 2D1) and CD45-V500C (BD phamingin, 2D1), and anti-IgD-APC (BD phamingin, IA6-2). The subsets of monocytes were detected using anti-HLA-DR-FITC (BD phamingin, L243), anti-CD16-PE (BD phamingin, B73.1), anti-CD14-APC (BD phamingin, MFP9), and anti-CD45-V500C (BD phamingin, 2D1). The expressions of inhibitory receptors on T cells were assessed using CD45-V500C (BD phamingin, 2D1), anti-CD4-APC-H7 (BD phamingin, RPA-T4), anti-CD8-PE/Cy7 (BD phamingin, SK1), anti-PD-1-V450 (Biolegend, EH12.2H7), and anti-TIGIT-PE (Biolegend, 15153G). Isotype controls with irrelevant specificities were included as negative controls. All of these cell suspensions were incubated for 20 min at room temperature. After lysing red blood cells with lysing solution, the cells were washed and re-suspended in 300 &#x3bc;l PBS. The cells were then analyzed with FACSCanto flow cytometer.</p>
</sec>
<sec id="s2_4">
<title>The Capability of Cytokine Secretion Analysis</title>
<p>Peripheral blood mononuclear cells (PBMCs) were isolated from heparinized venous whole blood by Ficoll-Hypaque density gradient centrifugation. In order to measure intracellular cytokines, PBMCs (2.5 &#xd7; 10<sup>5</sup>) were seeded in 96-well plates in 100 &#xb5;l of IMDM medium and stimulated with Leukocyte ActivationCocktail (Becton Dickinson GolgiPlug) for 4 h. After stimulation, the cells were collected and stained with the following monoclonal antibodies: anti-CD45-PerCP (BD phamingin, 2D1), anti-CD3-APC/H7 (BD phamingin, SK7), anti-CD4-V450 (BD phamingin, RPA-T4), and anti-CD8-PE/Cy7 (BD phamingin, SK1), followed by fixation and permeabilization, and staining with intracellular anti-IFN-&#x3b3;-APC (BD phamingin, B27) antibody, anti-TNF-&#x3b1;-FITC (Biolegend, MAb11), and anti-IL-2-PE (Biolegend, MQ1-17H12). The cells were then analyzed with FACSCanto flow cytometer.</p>
</sec>
<sec id="s2_5">
<title>Statistical Analysis</title>
<p>The results are presented as mean &#xb1; standard deviation (SD), or as median with interquartile range (IQR) when appropriate. Continuous variables were compared with Mann-Whitney U-test. Spearman&#x2019;s rank correlation test for non-parametric data was employed to analyze the relationship between two factors. Heatmaps were generated using R3.2.3 (R Foundation for Statistical Computing) with the pheatmap package 48. All variables with statistical significance were taken as candidates for multivariable logistic regression analyses. Receiver operating characteristic (ROC) curve analysis was performed to ascertain the optimal cutoff value of parameters associated with maximum sensitivity and specificity. Statistical analyses were performed using GraphPad Prism version 8 (San Diego, CA, USA) and SPSS version 22.0 SPSS, Chicago, IL, USA). Statistical significance was determined as <italic>p</italic> &lt; 0.05.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Participant Characteristics</title>
<p>The present study recruited 28 children diagnosed with IM, including 19 (67.9%) males and 9 (32.1%) females, median age of 6.0 (25<sup>th</sup>&#x2013;75<sup>th</sup> quartiles, range 3.9&#x2013;7.75 years). The most common clinical manifestations of the IM patients were enlarged tonsils (67.9%), pharyngeal hyperemia (64.3%), fever (60.7%), cervical lymphadenopathy (53.6%), and eyelid edema (46.4%). The clinical characteristics and laboratory test results of the included subjects are presented in <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Basic characteristics of pediatric patients with infectious mononucleosis.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="top" align="left"/>
<th valign="top" align="center">IM (n=28)</th>
<th valign="top" align="center">HC (n=18)</th>
<th valign="top" align="center">
<italic>p</italic> value </th>
</tr>
</thead>
<tbody>
<tr>
<td valign="top" align="left">
<bold>Age (years)</bold>
</td>
<td valign="top" align="center">6.0 (2.9-7.75)</td>
<td valign="top" align="center">5.58 (3.75-7.25)</td>
<td valign="top" align="center">0.942</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Gender</bold>
</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> Male</td>
<td valign="top" align="center">19 (67.9%)</td>
<td valign="top" align="center">9 (50%)</td>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> Female</td>
<td valign="top" align="center">9 (32.1%)</td>
<td valign="top" align="center">9 (50%)</td>
<td valign="top" align="center">0.354</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Clinic mainfestations</bold>
</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> Enlarged tonsills</td>
<td valign="top" align="center">19 (67.9%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> Pharyngeal hyperemia</td>
<td valign="top" align="center">18 (64.3%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> Fever</td>
<td valign="top" align="center">17 (60.7%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> Cervical lymphadenopathy</td>
<td valign="top" align="center">15 (53.6%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> Eyelid edema</td>
<td valign="top" align="center">13 (46.4%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> Sleep snoring</td>
<td valign="top" align="center">11 (39.3%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> Nasal obstruction</td>
<td valign="top" align="center">8 (28.6%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> Pharyngalgia</td>
<td valign="top" align="center">5 (17.9%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> Sniffles</td>
<td valign="top" align="center">5 (17.9%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> Cough</td>
<td valign="top" align="center">2 (7.1%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left">
<bold>Laboratory test</bold>
</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> Atypical lymphocytes (&gt;10%)</td>
<td valign="top" align="center">6 (21.4%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> Plasma EBV-DNA (copies/mL)</td>
<td valign="top" align="center">10 (35.7%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> EA IgG (U/mL)</td>
<td valign="top" align="center">16 (57.1%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> VCA IgG (U/mL)</td>
<td valign="top" align="center">21 (75.0%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> EBV IgM (U/mL)</td>
<td valign="top" align="center">26 (92.9%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> EBNA IgG (U/mL)</td>
<td valign="top" align="center">9 (32.1%)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
<tr>
<td valign="top" align="left"> WBC (&#xd7;10<sup>9</sup>/mL)</td>
<td valign="top" align="center">14.06&#xb1;5.29</td>
<td valign="top" align="center">7.10&#xb1;0.69</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left"> Neutrophils (&#xd7;10<sup>9</sup>/mL)</td>
<td valign="top" align="center">3.14&#xb1;0.37</td>
<td valign="top" align="center">3.32&#xb1;0.43</td>
<td valign="top" align="center">0.508</td>
</tr>
<tr>
<td valign="top" align="left"> Lymphocytes (&#xd7;10<sup>9</sup>/mL)</td>
<td valign="top" align="center">9.44&#xb1;0.64</td>
<td valign="top" align="center">3.36&#xb1;0.35</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left"> Platelets (&#xd7;10<sup>9</sup>/mL)</td>
<td valign="top" align="center">228.0&#xb1;15.11</td>
<td valign="top" align="center">315.9&#xb1;16.1</td>
<td valign="top" align="center">0.001</td>
</tr>
<tr>
<td valign="top" align="left"> Hemoglobin (g/L)</td>
<td valign="top" align="center">121.8&#xb1;1.48</td>
<td valign="top" align="center">128.1&#xb1;1.50</td>
<td valign="top" align="center">0.006</td>
</tr>
<tr>
<td valign="top" align="left"> ALT (U/mL)</td>
<td valign="top" align="center">104.5&#xb1;22.67</td>
<td valign="top" align="center">14.35&#xb1;1.36</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left"> AST (U/mL)</td>
<td valign="top" align="center">95.29&#xb1;17.93</td>
<td valign="top" align="center">23.71&#xb1;1.31</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left"> LDH (U/mL)</td>
<td valign="top" align="center">495.5&#xb1;156.7</td>
<td valign="top" align="center">214.1&#xb1;32.81</td>
<td valign="top" align="center">&lt;0.001</td>
</tr>
<tr>
<td valign="top" align="left">
<bold>Average days from symptom onset to sample collection</bold>
</td>
<td valign="top" align="center">6.0 (4.0-8.0)</td>
<td valign="top" align="center"/>
<td valign="top" align="center"/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn>
<p>Data are presented as number of patients (%) or median (25th-75th).</p>
</fn>
<fn>
<p>IM: EBV: Epstein-Barr Virus, VCA: viral capsid antigen, EA: early antigen, EBNA: EBV nuclear antigen. ALT: alanine aminotransferase, AST: aspartate aminotransferase, LDH: lactate dehydrogenase.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="s3_2">
<title>Characterization of Lymphocyte Subsets and Differential Phenotypes of Memory T Cells in Peripheral Blood</title>
<p>The lymphocyte subsets in peripheral blood were analyzed and revealed that the percentages and absolute numbers of CD3<sup>+</sup> T and CD8<sup>+</sup> T cells were significantly increased in IM patients compared with that of HCs. The percentages of CD4<sup>+</sup> T cells were relatively decreased but with no significant difference in absolute cell counts. Meanwhile, elevated numbers of NK cells were observed in IM patients but with decreased percentages and numbers of B cells (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1A, B</bold>
</xref>). The expression of CCR7 and CD45RA were used to distinguish the memory phenotypes of T cells (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>) (<xref ref-type="bibr" rid="B17">17</xref>). The results showed the percentages of CD4<sup>+</sup> and CD8<sup>+</sup> T Na&#xef;ve subtype (T<sub>Na&#xef;ve</sub>, CCR7<sup>+</sup> CD45RA<sup>+</sup>) in the IM group were decreased, and concomitantly with accumulated percentages of CD4<sup>+</sup> and CD8<sup>+</sup> T effector memory subtype (T<sub>EM</sub>, CCR7<sup>&#x2212;</sup> CD45RA<sup>&#x2212;</sup>) compared with that of HCs. The percentage of CD8<sup>+</sup> T central memory subtype (T<sub>CM</sub>, CCR7<sup>+</sup> CD45RA<sup>&#x2212;</sup>) was increased, but the percentage of terminally differentiated effector CD8<sup>+</sup> T subtype (T<sub>EMRA</sub>, CCR7<sup>&#x2212;</sup> CD45RA<sup>+</sup>) was decreased (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1C</bold>
</xref>). Furthermore, the proportions of regulatory T cells (Tregs, CD4<sup>+</sup>/CD25<sup>+</sup>/CD127<sup>low</sup>), including CD45RA<sup>+</sup> Na&#xef;ve Treg and CD45RA<sup>&#x2212;</sup>-induced Treg, were all significantly decreased in patients with IM than that of HCs (<xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1D</bold>
</xref>).</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>The lymphocyte subsets and immunophenotype characteristics. Circulating lymphocytes in pediatric patients newly diagnosed with infectious mononucleosis (IM) and healthy controls (HCs) were analyzed using flow cytometer. <bold>(A, B)</bold> The percentages and absolute numbers of T cells, B cells, and NK cells in different groups were expressed as mean with standard deviation (SD). <bold>(C)</bold> A typical example of the gating strategy is shown. CD4<sup>+</sup> and CD8<sup>+</sup> Na&#xef;ve (T<sub>Na&#xef;ve</sub>, CCR7<sup>+</sup> CD45RA<sup>+</sup>), central memory (T<sub>CM</sub>, CCR7<sup>+</sup> CD45RA<sup>&#x2212;</sup>), effector memory (T<sub>CM</sub> CCR7<sup>&#x2212;</sup> CD45RA<sup>&#x2212;</sup>), and EMRA (T<sub>EMRA</sub>, CCR7<sup>&#x2212;</sup> CD45RA<sup>+</sup>) T cell subsets were shown. The percentages of CD4<sup>+</sup> T and CD8<sup>+</sup> T cell subtypes in different groups were expressed as mean with SD. <bold>(D)</bold> Representative flow dot plots showing the gating of Tregs (CD4<sup>+</sup> CD25<sup>+</sup> CD127<sup>low</sup>), CD45RA<sup>+</sup> Tregs and CD45RA<sup>&#x2212;</sup> Tregs. The percentages of Tregs, CD45RA<sup>+</sup> Tregs, and CD45RA<sup>&#x2212;</sup> Tregs in lymphocytes were expressed as mean with SD. Blue circle points represent HCs, and red circle points represent IM patients. *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01, ***<italic>p</italic> &lt; 0.001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-753290-g001.tif"/>
</fig>
</sec>
<sec id="s3_3">
<title>CD4<sup>+</sup> and CD8<sup>+</sup> T Cells Exhibited Highly Activated Phenotypes in IM Patients</title>
<p>The immune-phenotypes of CD4<sup>+</sup> and CD8<sup>+</sup> T cells were determined through detecting the expression of activation, co-stimulatory, TCR, and inhibitory molecules. IM patients showed obviously high levels of HLA-DR expression in CD4<sup>+</sup> and CD8<sup>+</sup> T cells, but the expression of CD28 showed no significant difference (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2A, B</bold>
</xref>). Decreased expression of TCR-&#x3b1;&#x3b2; and increased expression of TCR-&#x3b3;&#x3b4; were observed in CD4<sup>+</sup> T cells, whereas converse results were observed in CD8<sup>+</sup> T cells. The ratio of TCR-&#x3b1;&#x3b2; and TCR-&#x3b3;&#x3b4; in CD4<sup>+</sup> T cells was decreased but increased in CD8<sup>+</sup> T cells (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2C, D</bold>
</xref>). CD8<sup>+</sup> T cells in IM patients also displayed significantly high levels of PD-1 and TIGIT, but not for CD4<sup>+</sup> T cells (<xref ref-type="fig" rid="f2">
<bold>Figures&#xa0;2E, F</bold>
</xref>). Furthermore, IM patients were stratified into two groups according to age (age 0&#x2013;5 years and 6&#x2013;13 years), and the lymphocyte numbers and phenotypes were analyzed. Our results showed that a higher percentage of CD3<sup>+</sup> T cells but lower counts of CD4<sup>+</sup> T cells and B cells were observed in older children than that of younger children (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures&#xa0;1A, B</bold>
</xref>). More percentages of naive CD8<sup>+</sup> T cells were differentiated into EM subsets in older children (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures&#xa0;1C, D</bold>
</xref>). However, the expression of CD28 and HLA-DR showed no significant difference between the two age groups (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures&#xa0;1E, F</bold>
</xref>). Notably, an increased proportion of CD8<sup>dim</sup> T cells along with robust CD8<sup>high</sup> and CD8<sup>dim</sup> T cell expansion were found in IM patients, and comparisons of active phenotypes between CD8<sup>high</sup> and CD8<sup>dim</sup> T cells were performed (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures&#xa0;2A, B</bold>
</xref>). Increased levels of HLA-DR and TCR in CD8<sup>high</sup> and CD8<sup>dim</sup> T cells and a high level of CD28 in CD8<sup>high</sup> T cells were observed in IM patients than HCs, but no significant differences of HLA-DR and CD28 were found between the two subpopulations (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Figures&#xa0;1C, D</bold>
</xref>). These data confirmed the robust expansion and highly active status of CD8<sup>+</sup> T cells in response to EBV infection.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p> Immunophenotype characteristics of T cells in IM patients. <bold>(A, B)</bold> Representative flow cytometry gating strategy for the expression of HLA-DR and CD28 in T cells. The percentages of HLA-DR and CD28 positive cells in CD4<sup>+</sup> and CD8<sup>+</sup> T cells from IM patients and HCs were expressed as mean with SD. <bold>(C)</bold> Representative dot plots showing the expression of TCR in CD4<sup>+</sup> and CD8<sup>+</sup> T cells. <bold>(D)</bold> The percentages of TCR-&#x3b1;&#x3b2; and TCR-&#x3b3;&#x3b4; positive cells and the ratio of TCR-&#x3b1;&#x3b2; and TCR-&#x3b3;&#x3b4; in CD4<sup>+</sup> and CD8<sup>+</sup> T cells were expressed as mean with SD. <bold>(E)</bold> Representative dot plots showing the expression of PD-1 and TIGIT in CD4<sup>+</sup> and CD8<sup>+</sup> T cells. <bold>(F)</bold> The percentages of PD-1 and TIGIT positive cells were expressed as mean with SD. Blue circle points represent HCs, and red circle points represent IM patients. ***<italic>p</italic> &lt; 0.001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-753290-g002.tif"/>
</fig>
</sec>
<sec id="s3_4">
<title>CD8<sup>+</sup> T Cells From IM Patients Showed Impaired Function of Cytokine Secretion</title>
<p>The cytokine secretion of CD4<sup>+</sup> and CD8<sup>+</sup> T cells were assessed after stimulation with PMA/ionomycin. The percentages of IL-2 single-positive and triple-cytokine-positive (IFN-&#x3b3;<sup>+</sup> TNF-&#x3b1;<sup>+</sup> IL-2<sup>+</sup>) CD4<sup>+</sup> T cells were decreased significantly in IM patients (<xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3A, B</bold>
</xref>). However, the percentages of single cytokine positive and multifunctional CD8<sup>+</sup> T cells (cytokine double positive and triple cytokine positive) were all decreased in IM group compared with that HCs (<xref ref-type="fig" rid="f3">
<bold>Figures&#xa0;3C, D</bold>
</xref>). These data suggested that although CD8<sup>+</sup> T cells are expanded and activated rapidly during the early stage of EBV infection, they exhibited impaired cytokine secretion capability after re-stimulation <italic>in vitro</italic>.</p>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>The cytokine secretion capability of T cells. PBMCs isolated from IM patients, and HCs were stimulated with PMA/ionomycin. After culture, the cells were collected and the production of intracellular IFN-&#x3b3;, TNF-&#x3b1;, and IL-2 in CD4<sup>+</sup> and CD8<sup>+</sup> T cells was analyzed by flow cytometry. <bold>(A)</bold> Representative dot plots showing the gating strategies for intracellular cytokines in CD4<sup>+</sup> T cells. CD4<sup>+</sup> T cells were shown, and the percentages of IL-2, IFN-&#x3b3;, and TNF-&#x3b1; single-positive, IL-2<sup>+</sup> TNF-&#x3b1;<sup>+</sup> and IFN-&#x3b3;<sup>+</sup> TNF-&#x3b1;<sup>+</sup> double-positive cells were gated. Then IFN-&#x3b3; single-positive cells were shown, and IFN-&#x3b3;<sup>+</sup> IL-2<sup>+</sup>, IFN-&#x3b3;<sup>+</sup> TNF-&#x3b1;<sup>+</sup> IL-2<sup>+</sup> cell populations were gated. <bold>(B)</bold> The percentages of IFN-&#x3b3;, TNF-&#x3b1;, and IL-2 single-, double-, and triple-positive cells within CD4<sup>+</sup> T cells from IM patients and HCs were expressed as mean with SD. <bold>(C)</bold> Representative dot plots showing the gating strategies for intracellular cytokines in CD8<sup>+</sup> T cells. <bold>(D)</bold> The percentages of IFN-&#x3b3;, TNF-&#x3b1;, and IL-2 single-, double-, and triple-positive cells within CD8<sup>+</sup> T cells from IM patients and HCs were expressed as mean with SD. Blue circle points represent HCs, and red circle points represent IM patients. *<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01, ***<italic>p</italic> &lt; 0.001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-753290-g003.tif"/>
</fig>
</sec>
<sec id="s3_5">
<title>Monocyte and B Cell Subsets in IM Patients</title>
<p>Monocytes exert innate immune response against viral infection, and the subsets of monocytes in IM were also assessed in the present study. Our results show that intermediate (CD14<sup>++</sup> CD16<sup>+</sup>) subsets were found to be increased in IM patients, but not for classic (CD14<sup>++</sup> CD16<sup>&#x2212;</sup>) and non-classic (CD14<sup>+</sup> CD16<sup>+</sup>) subsets. These results might be associated with the high inflammatory status of host immunity (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4A, B</bold>
</xref>). Meanwhile, EBV infects Na&#xef;ve (IgD<sup>+</sup> CD27<sup>&#x2212;</sup>) B cells and promotes their differentiation into memory cells, or infects memory (IgD<sup>&#x2212;</sup> CD27<sup>+</sup>) B cells directly. The percentages of Na&#xef;ve B cell subset were higher but with lower percentages of unswitched (IgD<sup>+</sup> CD27<sup>+</sup>) and memory B cells (<xref ref-type="fig" rid="f4">
<bold>Figures&#xa0;4C, D</bold>
</xref>) in IM patients. These data suggested that the differentiation of B cells might be dampened during the course of EBV infection.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>The subsets of monocytes and B cells. <bold>(A)</bold> Representative monocyte gating strategies in whole blood. CD45 <italic>vs.</italic> SSC plot: Broad selection of monocytes based on their SSC/CD45 properties. CD14 <italic>vs.</italic> CD16 plot: Gating to select monocytes based on their characteristic &#x201c;&#x2510;&#x201d; shape. CD16 <italic>vs.</italic> HLA-DR plot: Gating to select HLA-DR positive cells and remove NK cells. Selected monocytes redisplayed on CD16 <italic>vs.</italic> CD14 plot to gate the classical (CD14<sup>++</sup> CD16<sup>&#x2013;</sup>), non-classical monocyte (CD14<sup>+</sup> CD16<sup>+</sup>), and intermediate (CD14<sup>++</sup> CD16<sup>+</sup>) subsets. <bold>(B)</bold> The percentages of intermediate, non-classic, and classic monocytes from IM patients and HCs were expressed as mean and SD. <bold>(C)</bold> Representative flow dot plots showing the gating strategies of B cell subsets. CD19<sup>+</sup> cells were gated and subclassified into Na&#xef;ve (IgD<sup>+</sup> CD27<sup>&#x2212;</sup>), unswitched (IgD<sup>+</sup> CD27<sup>+</sup>), and memory (IgD<sup>&#x2212;</sup> CD27<sup>+</sup>) cell populations. Plasma cells were gated as CD27<sup>+</sup> CD38<sup>high</sup> cell population. <bold>(D)</bold> The percentages of B cell Na&#xef;ve, unswitched, memory, and plasma cells from IM patients and HCs were expressed as mean with SD. Blue circle points represent HCs, and red circle points represent IM patients. *<italic>p</italic> &lt; 0.05, ***<italic>p</italic> &lt; 0.001.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-753290-g004.tif"/>
</fig>
<p>Due to the heterogeneity of cell counts and immune marker expression among different individuals, a hierarchically clustered heatmap was developed for sample visualization (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>). The overall analysis of immune signatures showed that the expression of HLA-DR, the proportion of EM subsets in CD4<sup>+</sup> and CD8<sup>+</sup> T cells, and the absolute counts of CD3<sup>+</sup> and CD8<sup>+</sup> T cells were increased, but the percentages of CD4<sup>+</sup> T cells, B cells and Tregs, and naive subsets of CD4<sup>+</sup> and CD8<sup>+</sup> T cells were decreased in IM group compared with that HCs.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>Immunophenotypes of mononuclear cells were shown in a heatmap with unsupervised clustering analyses.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-753290-g005.tif"/>
</fig>
</sec>
<sec id="s3_6">
<title>Elevated Percentage of HLA-DR<sup>+</sup> CD8<sup>+</sup> T Cells Was Associated With the Clinical Severity of IM Patients</title>
<p>To investigate the association of immune signatures with clinical characteristics of IM, multivariate analysis was used, and the results revealed that the percentage of HLA-DR<sup>+</sup> CD8<sup>+</sup> T cells was the prominent factor for predicting the occurrence of IM (<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Table&#xa0;1</bold>
</xref>). ROC curve analysis suggested that the percentage of HLA-DR<sup>+</sup> CD8<sup>+</sup> T cells was an effective marker in distinguishing IM patients from HCs, with an AUC of 0.997 (95% CI 0.905&#x2013;1.000). The sensitivity and specificity of HLA-DR<sup>+</sup> CD8<sup>+</sup> T cell frequency at the best cutoff point (24%) were 95.24 and 100.0%, respectively. Then overall results of correlation analysis based on Spearman&#x2019;s rank coefficient test were presented. Our data showed that percentage of HLA-DR<sup>+</sup> CD8<sup>+</sup> T cells was significantly associated with high plasmid viral load, EBV IgM level, percentage of atypical lymphocytes in peripheral blood smear, and abnormal blood routine and liver function results (<xref ref-type="fig" rid="f6">
<bold>Figures&#xa0;6A&#x2013;H</bold>
</xref>). These data suggested that the elevated expression of HLA-DR in CD8<sup>+</sup> T cells correlates well with the development and clinical severity of IM.</p>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Correlation analysis between the percentage of HLA-DR<sup>+</sup> CD8<sup>+</sup> T cells and viral loaders and laboratory results. <bold>(A&#x2013;C)</bold> Correlation between the percentage HLA-DR<sup>+</sup> CD8<sup>+</sup> T cells and plasmid EBV DNA copies (data were log10 transformed), EBV IgM levels and the percentage of atypical lymphocytes in peripheral blood smear. <bold>(D, E)</bold> Correlation between the percentages of HLA-DR<sup>+</sup> CD8<sup>+</sup> T cells and the counts of leukocytes and lymphocytes were shown. <bold>(F&#x2013;H)</bold> Correlation between the percentages HLA-DR<sup>+</sup> CD8<sup>+</sup> T cells and the levels of ALT, AST, and LDH were shown. ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-12-753290-g006.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>EBV infection is one of the most common infections in children and the main cause of IM (<xref ref-type="bibr" rid="B18">18</xref>). It is a major pathogen which is a serious threat to children&#x2019;s health. EBV-IM is primarily transmitted through saliva contact, but it can also spread through blood, usually accompanied by an increase of atypical lymphocytes in peripheral blood. Although primary EBV infection is self-limited, it can be recurrent and associated with serious complications or poor prognosis in immune-deficiency patients (<xref ref-type="bibr" rid="B19">19</xref>). EBV infection is also one of the major causes of secondary HPS, which involves multiple organs and is life-threatening (<xref ref-type="bibr" rid="B20">20</xref>). Previous studies show that IM in childhood or adolescence had a 40% risk of subsequent diagnosis of depression, and excessive inflammatory is one key factor leading to depression (<xref ref-type="bibr" rid="B21">21</xref>, <xref ref-type="bibr" rid="B22">22</xref>). Therefore, IM is an immunopathology condition, and its symptoms are caused by an excessive immune response to EBV infection (<xref ref-type="bibr" rid="B23">23</xref>, <xref ref-type="bibr" rid="B24">24</xref>).</p>
<p>EBV infection initiates a polyclonal B cell proliferation and stimulates a vigorous immune response of CD8<sup>+</sup> T cells to eradicate infected B cells. Previous studies showed that a huge predominance of mononuclear cells in circulating peripheral blood is EBV-specific CD8<sup>+</sup> T cells in acute IM (<xref ref-type="bibr" rid="B25">25</xref>). In the present study, we observed noticeably increased counts of CD8<sup>+</sup> T cells, but not for CD4<sup>+</sup> T cells in response to EBV infection in a cohort of pediatric patients with IM compared with HCs, which was consistent with the previous studies (<xref ref-type="bibr" rid="B26">26</xref>). Further analysis revealed decreased percentages of Na&#xef;ve subsets, but increased percentages of T<sub>EM</sub> subsets for CD4<sup>+</sup> and CD8<sup>+</sup> T cells and T<sub>CM</sub> for CD8<sup>+</sup> T. These data demonstrated the rapid differentiation of Na&#xef;ve T cells into effector and memory T cells with the stimulation of viral antigen. When effector T cells migrate to the site of inflammation to fight infection, memory T cells are distributed to survey and prevent the recurrence of disease. T<sub>CM</sub> cells might lack effector properties, and T<sub>EM</sub> cells could respond quickly to reinfection with lytic activity. Both CD4<sup>+</sup> and CD8<sup>+</sup> T<sub>EM</sub> cells are characterized by rapid effector function in producing IFN-&#x3b3;, IL-4, and IL-5 than T<sub>CM</sub> cells upon antigenic stimulation (<xref ref-type="bibr" rid="B27">27</xref>). Therefore, much larger reservoir of memory CD8<sup>+</sup> T cells and the balance between T<sub>CM</sub> and T<sub>EM</sub> are essential in immune control of persistent viral infections (<xref ref-type="bibr" rid="B26">26</xref>, <xref ref-type="bibr" rid="B28">28</xref>, <xref ref-type="bibr" rid="B29">29</xref>).</p>
<p>Immunophenotype analysis of T cells in children with IM showed significant activation of CD4<sup>+</sup> and CD8<sup>+</sup> T cells by detecting HLA-DR expression. Previous studies show that 34&#x2013;54% of the HLA-DR<sup>+</sup> CD8<sup>+</sup> T cells in PBMCs were EBV-specific in febrile patients. The decline of HLA-DR<sup>+</sup> CD8<sup>+</sup> T cells was in parallel with reduction of EBV load (<xref ref-type="bibr" rid="B30">30</xref>). The upregulation of HLA-DR on CD8<sup>+</sup> T cells was also reported in other virus infection, such as influenza, SARS, and Dengue (<xref ref-type="bibr" rid="B31">31</xref>&#x2013;<xref ref-type="bibr" rid="B33">33</xref>). Therefore, effective expansion of reactive CD8<sup>+</sup> T cells is needed for early protection against EBV infection. In addition, TCR is an important determinant of CD8<sup>+</sup> T cell-mediated antiviral efficacy or immune-mediated pathogenesis (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B35">35</xref>). TCR-&#x3b1;&#x3b2; of CD8<sup>+</sup> T cell responses to common viruses (influenza virus, cytomegalovirus) is favored for expansion due to the selection for optimal structural interaction (<xref ref-type="bibr" rid="B36">36</xref>). Our results indicated elevated TCR-&#x3b1;&#x3b2; in CD8<sup>+</sup> T cells, which correlated with virologic control and facilitated our understanding of how EBV-specific CD8<sup>+</sup> T cells control EBV replication. Both CD8<sup>high</sup> and CD8<sup>dim</sup> T cells seemed to be highly activated, and the active phenotypes of CTL suggested the key role of these effector cells in eliminating EBV infection.</p>
<p>Our results showed an increased frequency of inhibitory molecules PD-1 and TIGIT on the surface of CD8<sup>+</sup> T cells. Previous studies suggested that the upregulation of inhibitory receptors in CD8<sup>+</sup> T cells correlates with dysfunction, and exhausted PD-1 expressing EBV-specific T cells lead to the loss of EBV control (<xref ref-type="bibr" rid="B37">37</xref>). In contrast, some studies showed that PD-1<sup>+</sup> cells retain their proliferative, cytokine secretion, and cytotoxic capacities (<xref ref-type="bibr" rid="B38">38</xref>). Therefore, the functional heterogeneity of PD-1 might need further investigation. Moreover, we observed the decrease of multiple cytokines (IFN-&#x3b3;, TNF-, IL-2) after stimulation of PMA/ionomycin, including single cytokine-positive and multifunctional CD4<sup>+</sup> and CD8<sup>+</sup> T cells. These data indicated that T cells, especially CD8<sup>+</sup> T cells, become exhausted progressively in the course of EBV elimination in response to persistent antigen stimulation. Furthermore, multivariate analysis revealed that the percentage of HLA-DR<sup>+</sup> CD8<sup>+</sup> T cells was an independent prognostic marker for IM and significantly associated with the viral load and illness severity. The percentage of HLA-DR-expressing CD8<sup>+</sup> T cell showed high sensitivity and specificity to distinguish IM patients from HCs. Therefore, HLA-DR<sup>+</sup> CD8<sup>+</sup> T cells could be used for the early screening, and help in the assessment of clinical severity of children with IM.</p>
<p>Several limitations of the present study should be mentioned. First, a larger number of children, especially those with immunocompromised status, are warranted to determine the alterations of mononuclear cell phenotypes in response to EBV infection. Second, antigen-specific T and B cell detection requires further investigation to claim the specific immune response in IM. Third, dynamic monitoring of immune signatures during EBV infection should be done for predicting the prognosis of IM.</p>
</sec>
<sec id="s5">
<title>Conclusion</title>
<p>Collectively, this study assessed the numbers, phenotypes, and functions of lymphocytes and demonstrated the highly active phenotypes but impaired function of T cells during acute EBV infection. In addition, the change of CD8<sup>+</sup> T cells was focused to be the prominent marker associated with the severity of children with IM. The evaluation of immunophenotypes not only extends further understanding of the pathogenesis of IM, but also may have valuable implications for guiding the diagnosis and therapy of the disease.</p>
</sec>
<sec id="s6" sec-type="data-availability">
<title>Data Availability Statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">
<bold>Supplementary Material</bold>
</xref>. Further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s7" sec-type="ethics-statement">
<title>Ethics Statement</title>
<p>The studies involving human participants were reviewed and approved by the ethical committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Written informed consent to participate in this study was provided by the participants&#x2019; legal guardian/next of kin. Written informed consent was obtained from the individual(s), and minor(s)&#x2019; legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec id="s8" sec-type="author-contributions">
<title>Author Contributions</title>
<p>YW and HH wrote the manuscript. YL, GT, RO, and MZ collected the materials of patients. YJ, TW, BY, and WW did the flow cytometry. XZ, JH, and MH analyzed the data. FW and SW helped revise the manuscript. All authors contributed to the article and approved the submitted version.</p>
</sec>
<sec id="s9" sec-type="funding-information">
<title>Funding</title>
<p>This study was funded by the National Mega Project on Major Infectious Disease Prevention (2017ZX10103005-007).</p>
</sec>
<sec id="s10" sec-type="COI-statement">
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s11" sec-type="disclaimer">
<title>Publisher&#x2019;s Note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
</body>
<back>
<sec id="s12" sec-type="supplementary-material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fimmu.2021.753290/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fimmu.2021.753290/full#supplementary-material</ext-link>
</p>
<supplementary-material xlink:href="Image_1.tif" id="SM1" mimetype="image/tiff"/>
<supplementary-material xlink:href="Image_2.tif" id="SM2" mimetype="image/tiff"/>
<supplementary-material xlink:href="Table_1.docx" id="SM3" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document"/>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luzuriaga</surname> <given-names>K</given-names>
</name>
<name>
<surname>Sullivan</surname> <given-names>JL</given-names>
</name>
</person-group>. <article-title>Infectious Mononucleosis</article-title>. <source>N Engl J Med</source> (<year>2010</year>) <volume>362</volume>(<issue>21</issue>):<fpage>1993</fpage>&#x2013;<lpage>2000</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJMcp1001116</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vouloumanou</surname> <given-names>EK</given-names>
</name>
<name>
<surname>Rafailidis</surname> <given-names>PI</given-names>
</name>
<name>
<surname>Falagas</surname> <given-names>ME</given-names>
</name>
</person-group>. <article-title>Current Diagnosis and Management of Infectious Mononucleosis</article-title>. <source>Curr Opin Hematol</source> (<year>2012</year>) <volume>19</volume>(<issue>1</issue>):<fpage>14</fpage>&#x2013;<lpage>20</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/MOH.0b013e32834daa08</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Luo</surname> <given-names>L</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>Q</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>J</given-names>
</name>
</person-group>. <article-title>Diagnostic Value of Serological and Molecular Biological Tests for Infectious Mononucleosis by EBV in Different Age Stages and Course of the Disease</article-title>. <source>J Med Virol</source> (<year>2021</year>) <volume>93</volume>(<issue>6</issue>):<page-range>3824&#x2013;34</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jmv.26558</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ma</surname> <given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Zu</surname> <given-names>D</given-names>
</name>
<name>
<surname>Gu</surname> <given-names>F</given-names>
</name>
<name>
<surname>Ding</surname> <given-names>X</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical Manifestations and Laboratory Results of 61 Children With Infectious Mononucleosis</article-title>. <source>J Int Med Res</source> (<year>2020</year>) <volume>48</volume>(<issue>10</issue>):<elocation-id>300060520924550</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/0300060520924550</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname> <given-names>G</given-names>
</name>
<name>
<surname>Xie</surname> <given-names>ZD</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>KL</given-names>
</name>
</person-group>. <article-title>[Attach Importance to Diseases Associated With Severe Epstein-Barr Virus Infection in Children]</article-title>. <source>Zhonghua Er Ke Za Zhi</source> (<year>2016</year>) <volume>54</volume>(<issue>8</issue>):<page-range>561&#x2013;2</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3760/cma.j.issn.0578-1310.2016.08.001</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dunmire</surname> <given-names>SK</given-names>
</name>
<name>
<surname>Verghese</surname> <given-names>PS</given-names>
</name>
<name>
<surname>Balfour</surname> <given-names>HH</given-names> <suffix>Jr.</suffix>
</name>
</person-group> <article-title>Primary Epstein-Barr Virus Infection</article-title>. <source>J Clin Virol</source> (<year>2018</year>) <volume>102</volume>:<fpage>84</fpage>&#x2013;<lpage>92</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jcv.2018.03.001</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sylvester</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Buchanan</surname> <given-names>BK</given-names>
</name>
<name>
<surname>Paradise</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Yauger</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Beutler</surname> <given-names>AI</given-names>
</name>
</person-group>. <article-title>Association of Splenic Rupture and Infectious Mononucleosis: A Retrospective Analysis and Review of Return-to-Play Recommendations</article-title>. <source>Sports Health</source> (<year>2019</year>) <volume>11</volume>(<issue>6</issue>):<page-range>543&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1177/1941738119873665</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Balfour</surname> <given-names>HH</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Holman</surname> <given-names>CJ</given-names>
</name>
<name>
<surname>Hokanson</surname> <given-names>KM</given-names>
</name>
<name>
<surname>Lelonek</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Giesbrecht</surname> <given-names>JE</given-names>
</name>
<name>
<surname>White</surname> <given-names>DR</given-names>
</name>
<etal/>
</person-group>. <article-title>A Prospective Clinical Study of Epstein-Barr Virus and Host Interactions During Acute Infectious Mononucleosis</article-title>. <source>J Infect Dis</source> (<year>2005</year>) <volume>192</volume>(<issue>9</issue>):<page-range>1505&#x2013;12</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1086/491740</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Niederman</surname> <given-names>JC</given-names>
</name>
<name>
<surname>Miller</surname> <given-names>G</given-names>
</name>
<name>
<surname>Pearson</surname> <given-names>HA</given-names>
</name>
<name>
<surname>Pagano</surname> <given-names>JS</given-names>
</name>
<name>
<surname>Dowaliby</surname> <given-names>JM</given-names>
</name>
</person-group>. <article-title>Infectious Mononucleosis. Epstein-Barr-Virus Shedding in Saliva and the Oropharynx</article-title>. <source>N Engl J Med</source> (<year>1976</year>) <volume>294</volume>(<issue>25</issue>):<page-range>1355&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJM197606172942501</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Babcock</surname> <given-names>GJ</given-names>
</name>
<name>
<surname>Decker</surname> <given-names>LL</given-names>
</name>
<name>
<surname>Freeman</surname> <given-names>RB</given-names>
</name>
<name>
<surname>Thorley-Lawson</surname> <given-names>DA</given-names>
</name>
</person-group>. <article-title>Epstein-Barr Virus-Infected Resting Memory B Cells, Not Proliferating Lymphoblasts, Accumulate in the Peripheral Blood of Immunosuppressed Patients</article-title>. <source>J Exp Med</source> (<year>1999</year>) <volume>190</volume>(<issue>4</issue>):<page-range>567&#x2013;76</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1084/jem.190.4.567</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crawford</surname> <given-names>DH</given-names>
</name>
</person-group>. <article-title>Biology and Disease Associations of Epstein-Barr Virus</article-title>. <source>Philos Trans R Soc Lond B Biol Sci</source> (<year>2001</year>) <volume>356</volume>(<issue>1408</issue>):<page-range>461&#x2013;73</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1098/rstb.2000.0783</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Callan</surname> <given-names>MF</given-names>
</name>
<name>
<surname>Steven</surname> <given-names>N</given-names>
</name>
<name>
<surname>Krausa</surname> <given-names>P</given-names>
</name>
<name>
<surname>Wilson</surname> <given-names>JD</given-names>
</name>
<name>
<surname>Moss</surname> <given-names>PA</given-names>
</name>
<name>
<surname>Gillespie</surname> <given-names>GM</given-names>
</name>
<etal/>
</person-group>. <article-title>Large Clonal Expansions of CD8+ T Cells in Acute Infectious Mononucleosis</article-title>. <source>Nat Med</source> (<year>1996</year>) <volume>2</volume>(<issue>8</issue>):<page-range>906&#x2013;11</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nm0896-906</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tomkinson</surname> <given-names>BE</given-names>
</name>
<name>
<surname>Wagner</surname> <given-names>DK</given-names>
</name>
<name>
<surname>Nelson</surname> <given-names>DL</given-names>
</name>
<name>
<surname>Sullivan</surname> <given-names>JL</given-names>
</name>
</person-group>. <article-title>Activated Lymphocytes During Acute Epstein-Barr Virus Infection</article-title>. <source>J Immunol</source> (<year>1987</year>) <volume>139</volume>(<issue>11</issue>):<page-range>3802&#x2013;7</page-range>.</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yajima</surname> <given-names>M</given-names>
</name>
<name>
<surname>Imadome</surname> <given-names>K</given-names>
</name>
<name>
<surname>Nakagawa</surname> <given-names>A</given-names>
</name>
<name>
<surname>Watanabe</surname> <given-names>S</given-names>
</name>
<name>
<surname>Terashima</surname> <given-names>K</given-names>
</name>
<name>
<surname>Nakamura</surname> <given-names>H</given-names>
</name>
<etal/>
</person-group>. <article-title>T Cell-Mediated Control of Epstein-Barr Virus Infection in Humanized Mice</article-title>. <source>J Infect Dis</source> (<year>2009</year>) <volume>200</volume>(<issue>10</issue>):<page-range>1611&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1086/644644</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname> <given-names>JI</given-names>
</name>
</person-group>. <article-title>Primary Immunodeficiencies Associated With EBV Disease</article-title>. <source>Curr Top Microbiol Immunol</source> (<year>2015</year>) <volume>390</volume>(<issue>Pt 1</issue>):<page-range>241&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/978-3-319-22822-8_10</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Munz</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Epstein Barr Virus - A Tumor Virus That Needs Cytotoxic Lymphocytes to Persist Asymptomatically</article-title>. <source>Curr Opin Virol</source> (<year>2016</year>) <volume>20</volume>:<page-range>34&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.coviro.2016.08.010</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Workman</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Mahe</surname> <given-names>MM</given-names>
</name>
<name>
<surname>Trisno</surname> <given-names>S</given-names>
</name>
<name>
<surname>Poling</surname> <given-names>HM</given-names>
</name>
<name>
<surname>Watson</surname> <given-names>CL</given-names>
</name>
<name>
<surname>Sundaram</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Engineered Human Pluripotent-Stem-Cell-Derived Intestinal Tissues With a Functional Enteric Nervous System</article-title>. <source>Nat Med</source> (<year>2017</year>) <volume>23</volume>(<issue>1</issue>):<fpage>49</fpage>&#x2013;<lpage>59</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nm.4233</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cohen</surname> <given-names>JI</given-names>
</name>
</person-group>. <article-title>Epstein-Barr Virus Infection</article-title>. <source>N Engl J Med</source> (<year>2000</year>) <volume>343</volume>(<issue>7</issue>):<page-range>481&#x2013;92</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1056/NEJM200008173430707</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>F</given-names>
</name>
</person-group>. <article-title>Clinical Characteristics of Primary and Reactivated Epstein-Barr Virus Infection in Children</article-title>. <source>J Med Virol</source> (<year>2020</year>). doi:&#xa0;<pub-id pub-id-type="doi">10.1002/jmv.26202</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname> <given-names>J</given-names>
</name>
<name>
<surname>Chu</surname> <given-names>C</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>M</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Fan</surname> <given-names>Y</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical Warning of Hemophagocytic Syndrome Caused by Epstein-Barr Virus</article-title>. <source>Ital J Pediatr</source> (<year>2021</year>) <volume>47</volume>(<issue>1</issue>):<elocation-id>3</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13052-020-00949-7</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vindegaard</surname> <given-names>N</given-names>
</name>
<name>
<surname>Petersen</surname> <given-names>LV</given-names>
</name>
<name>
<surname>Lyng-Rasmussen</surname> <given-names>BI</given-names>
</name>
<name>
<surname>Dalsgaard</surname> <given-names>S</given-names>
</name>
<name>
<surname>Benros</surname> <given-names>ME</given-names>
</name>
</person-group>. <article-title>Infectious Mononucleosis as a Risk Factor for Depression: A Nationwide Cohort Study</article-title>. <source>Brain Behav Immun</source> (<year>2021</year>) <volume>94</volume>:<page-range>259&#x2013;65</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.bbi.2021.01.035</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Glaser</surname> <given-names>R</given-names>
</name>
<name>
<surname>Litsky</surname> <given-names>ML</given-names>
</name>
<name>
<surname>Padgett</surname> <given-names>DA</given-names>
</name>
<name>
<surname>Baiocchi</surname> <given-names>RA</given-names>
</name>
<name>
<surname>Yang</surname> <given-names>EV</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>EBV-Encoded Dutpase Induces Immune Dysregulation: Implications for the Pathophysiology of EBV-Associated Disease</article-title>. <source>Virology</source> (<year>2006</year>) <volume>346</volume>(<issue>1</issue>):<page-range>205&#x2013;18</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.virol.2005.10.034</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Silins</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Sherritt</surname> <given-names>MA</given-names>
</name>
<name>
<surname>Silleri</surname> <given-names>JM</given-names>
</name>
<name>
<surname>Cross</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Elliott</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Bharadwaj</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Asymptomatic Primary Epstein-Barr Virus Infection Occurs in the Absence of Blood T-Cell Repertoire Perturbations Despite High Levels of Systemic Viral Load</article-title>. <source>Blood</source> (<year>2001</year>) <volume>98</volume>(<issue>13</issue>):<page-range>3739&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1182/blood.v98.13.3739</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jayasooriya</surname> <given-names>S</given-names>
</name>
<name>
<surname>de Silva</surname> <given-names>TI</given-names>
</name>
<name>
<surname>Njie-jobe</surname> <given-names>J</given-names>
</name>
<name>
<surname>Sanyang</surname> <given-names>C</given-names>
</name>
<name>
<surname>Leese</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Bell</surname> <given-names>AI</given-names>
</name>
<etal/>
</person-group>. <article-title>Early Virological and Immunological Events in Asymptomatic Epstein-Barr Virus Infection in African Children</article-title>. <source>PloS Pathog</source> (<year>2015</year>) <volume>11</volume>(<issue>3</issue>):<fpage>e1004746</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.ppat.1004746</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shapiro</surname> <given-names>M</given-names>
</name>
<name>
<surname>Duca</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Lee</surname> <given-names>K</given-names>
</name>
<name>
<surname>Delgado-Eckert</surname> <given-names>E</given-names>
</name>
<name>
<surname>Hawkins</surname> <given-names>J</given-names>
</name>
<name>
<surname>Jarrah</surname> <given-names>AS</given-names>
</name>
<etal/>
</person-group>. <article-title>A Virtual Look at Epstein-Barr Virus Infection: Simulation Mechanism</article-title>. <source>J Theor Biol</source> (<year>2008</year>) <volume>252</volume>(<issue>4</issue>):<page-range>633&#x2013;48</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.jtbi.2008.01.032</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sulik</surname> <given-names>A</given-names>
</name>
<name>
<surname>Oldak</surname> <given-names>E</given-names>
</name>
<name>
<surname>Kroten</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lipska</surname> <given-names>A</given-names>
</name>
<name>
<surname>Radziwon</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Epstein-Barr Virus Effect on Frequency of Functionally Distinct T Cell Subsets in Children With Infectious Mononucleosis</article-title>. <source>Adv Med Sci</source> (<year>2014</year>) <volume>59</volume>(<issue>2</issue>):<page-range>227&#x2013;31</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.advms.2014.04.003</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sallusto</surname> <given-names>F</given-names>
</name>
<name>
<surname>Geginat</surname> <given-names>J</given-names>
</name>
<name>
<surname>Lanzavecchia</surname> <given-names>A</given-names>
</name>
</person-group>. <article-title>Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance</article-title>. <source>Annu Rev Immunol</source> (<year>2004</year>) <volume>22</volume>:<page-range>745&#x2013;63</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1146/annurev.immunol.22.012703.104702</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scherrenburg</surname> <given-names>J</given-names>
</name>
<name>
<surname>Piriou</surname> <given-names>ER</given-names>
</name>
<name>
<surname>Nanlohy</surname> <given-names>NM</given-names>
</name>
<name>
<surname>van Baarle</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Detailed Analysis of Epstein-Barr Virus-Specific CD4+ and CD8+ T Cell Responses During Infectious Mononucleosis</article-title>. <source>Clin Exp Immunol</source> (<year>2008</year>) <volume>153</volume>(<issue>2</issue>):<page-range>231&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/j.1365-2249.2008.03699.x</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tussey</surname> <given-names>L</given-names>
</name>
<name>
<surname>Speller</surname> <given-names>S</given-names>
</name>
<name>
<surname>Gallimore</surname> <given-names>A</given-names>
</name>
<name>
<surname>Vessey</surname> <given-names>R</given-names>
</name>
</person-group>. <article-title>Functionally Distinct CD8+ Memory T Cell Subsets in Persistent EBV Infection Are Differentiated by Migratory Receptor Expression</article-title>. <source>Eur J Immunol</source> (<year>2000</year>) <volume>30</volume>(<issue>7</issue>):<page-range>1823&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/1521-4141(200007)30:7&lt;1823::AID-IMMU1823&gt;3.0.CO;2-6</pub-id>
</citation>
</ref>
<ref id="B30">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hoshino</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Morishima</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kimura</surname> <given-names>H</given-names>
</name>
<name>
<surname>Nishikawa</surname> <given-names>K</given-names>
</name>
<name>
<surname>Tsurumi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Kuzushima</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Antigen-Driven Expansion and Contraction of CD8+-Activated T Cells in Primary EBV Infection</article-title>. <source>J Immunol</source> (<year>1999</year>) <volume>163</volume>(<issue>10</issue>):<page-range>5735&#x2013;40</page-range>.</citation>
</ref>
<ref id="B31">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Zhu</surname> <given-names>L</given-names>
</name>
<name>
<surname>Nguyen</surname> <given-names>THO</given-names>
</name>
<name>
<surname>Wan</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Sant</surname> <given-names>S</given-names>
</name>
<name>
<surname>Quinones-Parra</surname> <given-names>SM</given-names>
</name>
<etal/>
</person-group>. <article-title>Clonally Diverse CD38(+)HLA-DR(+)CD8(+) T Cells Persist During Fatal H7N9 Disease</article-title>. <source>Nat Commun</source> (<year>2018</year>) <volume>9</volume>(<issue>1</issue>):<fpage>824</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/s41467-018-03243-7</pub-id>
</citation>
</ref>
<ref id="B32">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalicinska</surname> <given-names>E</given-names>
</name>
<name>
<surname>Szymczak</surname> <given-names>D</given-names>
</name>
<name>
<surname>Andrasiak</surname> <given-names>I</given-names>
</name>
<name>
<surname>Bogucka-Fedorczuk</surname> <given-names>A</given-names>
</name>
<name>
<surname>Zinczuk</surname> <given-names>A</given-names>
</name>
<name>
<surname>Szymanski</surname> <given-names>W</given-names>
</name>
<etal/>
</person-group>. <article-title>Lymphocyte Subsets in Haematological Patients With COVID-19: Multicentre Prospective Study</article-title>. <source>Transl Oncol</source> (<year>2021</year>) <volume>14</volume>(<issue>1</issue>):<elocation-id>100943</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/j.tranon.2020.100943</pub-id>
</citation>
</ref>
<ref id="B33">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chandele</surname> <given-names>A</given-names>
</name>
<name>
<surname>Sewatanon</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gunisetty</surname> <given-names>S</given-names>
</name>
<name>
<surname>Singla</surname> <given-names>M</given-names>
</name>
<name>
<surname>Onlamoon</surname> <given-names>N</given-names>
</name>
<name>
<surname>Akondy</surname> <given-names>RS</given-names>
</name>
<etal/>
</person-group>. <article-title>Characterization of Human CD8 T Cell Responses in Dengue Virus-Infected Patients From India</article-title>. <source>J Virol</source> (<year>2016</year>) <volume>90</volume>(<issue>24</issue>):<page-range>11259&#x2013;78</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1128/JVI.01424-16</pub-id>
</citation>
</ref>
<ref id="B34">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Attaf</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sewell</surname> <given-names>AK</given-names>
</name>
</person-group>. <article-title>Disease Etiology and Diagnosis by TCR Repertoire Analysis Goes Viral</article-title>. <source>Eur J Immunol</source> (<year>2016</year>) <volume>46</volume>(<issue>11</issue>):<page-range>2516&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/eji.201646649</pub-id>
</citation>
</ref>
<ref id="B35">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miles</surname> <given-names>JJ</given-names>
</name>
<name>
<surname>Douek</surname> <given-names>DC</given-names>
</name>
<name>
<surname>Price</surname> <given-names>DA</given-names>
</name>
</person-group>. <article-title>Bias in the Alphabeta T-Cell Repertoire: Implications for Disease Pathogenesis and Vaccination</article-title>. <source>Immunol Cell Biol</source> (<year>2011</year>) <volume>89</volume>(<issue>3</issue>):<page-range>375&#x2013;87</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/icb.2010.139</pub-id>
</citation>
</ref>
<ref id="B36">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Song</surname> <given-names>I</given-names>
</name>
<name>
<surname>Gil</surname> <given-names>A</given-names>
</name>
<name>
<surname>Mishra</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ghersi</surname> <given-names>D</given-names>
</name>
<name>
<surname>Selin</surname> <given-names>LK</given-names>
</name>
<name>
<surname>Stern</surname> <given-names>LJ</given-names>
</name>
</person-group>. <article-title>Broad TCR Repertoire and Diverse Structural Solutions for Recognition of an Immunodominant CD8(+) T Cell Epitope</article-title>. <source>Nat Struct Mol Biol</source> (<year>2017</year>) <volume>24</volume>(<issue>4</issue>):<fpage>395</fpage>&#x2013;<lpage>406</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1038/nsmb.3383</pub-id>
</citation>
</ref>
<ref id="B37">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Larsen</surname> <given-names>M</given-names>
</name>
<name>
<surname>Sauce</surname> <given-names>D</given-names>
</name>
<name>
<surname>Deback</surname> <given-names>C</given-names>
</name>
<name>
<surname>Arnaud</surname> <given-names>L</given-names>
</name>
<name>
<surname>Mathian</surname> <given-names>A</given-names>
</name>
<name>
<surname>Miyara</surname> <given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Exhausted Cytotoxic Control of Epstein-Barr Virus in Human Lupus</article-title>. <source>PloS Pathog</source> (<year>2011</year>) <volume>7</volume>(<issue>10</issue>):<fpage>e1002328</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.ppat.1002328</pub-id>
</citation>
</ref>
<ref id="B38">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chatterjee</surname> <given-names>B</given-names>
</name>
<name>
<surname>Deng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Holler</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nunez</surname> <given-names>N</given-names>
</name>
<name>
<surname>Azzi</surname> <given-names>T</given-names>
</name>
<name>
<surname>Vanoaica</surname> <given-names>LD</given-names>
</name>
<etal/>
</person-group>. <article-title>CD8+ T Cells Retain Protective Functions Despite Sustained Inhibitory Receptor Expression During Epstein-Barr Virus Infection In Vivo</article-title>. <source>PloS Pathog</source> (<year>2019</year>) <volume>15</volume>(<issue>5</issue>):<fpage>e1007748</fpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1371/journal.ppat.1007748</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>